Martin Shkreli, the "pharma", sues the directors of Retrophin



[ad_1]

Martin Shkreli, former President and CEO of Turing Pharmaceuticals AG, arrives at Brooklyn District Federal Court in New York on Monday, July 31, 2017.

Peter Foley | Bloomberg | Getty Images

The well-known "pharma" Martin Shkreli on Friday sued two directors and the former general counsel of his former biopharmaceutical company, Retrophin, accusing them of using fraud to overthrow him at the head of the company. 2014.

Shkreli's lawsuit, filed in federal court in Manhattan, claims more than $ 30 million in damages.

He was housed a few days after 36-year-old Shkreli was transferred to a new Pennsylvania prison, where he will continue to serve a seven-year sentence for securities fraud related to his two missing hedge funds and to Retrophin, which He founded after the funds collapsed financially.

The defendants named in the case are Gary Lyons, chairman of Retrophin 's board of directors, Stephen Aselage, former CEO of the company, currently a director, and Margaret Valeur – Jensen, a former lawyer with the company.

"After creating a biopharmaceutical company from scratch and turning it into a thriving business worth hundreds of millions of dollars, Mr. Shkreli was evicted without ceremony and illegally from the company in the hands of the defendants," says the lawsuit.

"The defendants, who had little to do with the success of the company but were motivated by their ego, jealousy and greed, managed only one goal: to create and implement a plan to to oust Mr. Shkreli from society for their selfish advantage, "says the suit.

"Indeed, the only people who benefited from Mr. Shkreli's ouster were the three defendants and some other people that they recruited."

Shkreli's attorney in the Edward Kang case, of Philadelphia, declined to comment when he was contacted by CNBC.

A spokesman for Retrophin declined to comment.

Value-Jensen did not immediately return a comment request sent via his LinkedIn account.

Shkreli gained national prominence in 2015 after the company he created after his removal of Retrophin – Turing Pharmaceuticals – raised the price of his drug Daraprim by more than 5,000%.

The drug is used to treat a parasitic infection in pregnant women, babies and HIV patients. Turing is now known as Phoenixus AG.

In August 2017, a jury found Shkreli guilty of three of the eight charges related to his hedge funds and Retrophin. His $ 5 million bond was revoked a month later after his trial judge found it dangerous because of his offer to his Facebook subscribers of a $ 5,000 premium for hair samples. Hillary Clinton.

Since last year, he was serving his criminal sentence in the low-security prison of Fort Dix, NJ.

But two months ago, he was transferred to a federal prison in Brooklyn, New York, after the Wall Street Journal announced in March that he was still helping to "trigger" Phoenixus in the US. helping a smuggled mobile phone in Fort Dix.

This week, Shkreli was transferred to another low-security prison in Allenwood, Pennsylvania, according to the Bureau of Prisons website.

[ad_2]
Source link